Business Context and Reporting Period
This Form 8-K filing by Bristol-Myers Squibb Company reports the results of the Annual Meeting of Stockholders held on May 3, 2011. The filing details the voting outcomes for director elections, auditor ratification, executive compensation advisory votes, and several stockholder proposals.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
- Director Elections: All 12 nominees were elected to serve until the 2012 Annual Meeting. Votes ranged from approximately 1.04 billion to 1.15 billion "For" votes.
- Auditor Ratification: Deloitte & Touche LLP was ratified as the independent registered public accounting firm for 2011 with 1.42 billion votes "For" and 34.3 million "Against".
- Executive Compensation (Say-on-Pay): The advisory vote on executive compensation was approved with 1.09 billion votes "For" and 60.2 million "Against".
- Frequency of Say-on-Pay: Stockholders voted to hold the advisory vote on executive compensation annually (1-year frequency) with 625 million votes, compared to 508 million for a 3-year frequency.
- Stockholder Proposals:
- Executive Compensation Disclosure: Defeated (85.8 million "For" vs. 1.07 billion "Against").
- Stockholder Action by Written Consent: Defeated (444 million "For" vs. 705 million "Against").
- Pharmaceutical Price Restraint: Defeated (33.3 million "For" vs. 888 million "Against").
Guidance, Outlook, and Management Commentary
Management noted that the Board of Directors has taken into consideration the stockholders' views regarding the frequency of the advisory vote on executive compensation. Consequently, the Board decided to include an annual advisory vote on executive compensation in the Company's proxy materials until the next required vote on frequency. No financial guidance or outlook was provided in this filing.
Important Facts for Investor Verification
- Verify the Board's commitment to annual "Say-on-Pay" votes as a result of the May 3, 2011 shareholder decision.
- Confirm the re-election of the full slate of 12 directors, noting the specific vote counts for any directors receiving significant "Against" votes (e.g., Louis J. Freeh received over 105 million "Against" votes).
- Review the significant rejection of the stockholder proposal regarding pharmaceutical price restraint, indicating strong opposition from the majority of voting shareholders.
- Check subsequent filings for the official appointment of Deloitte & Touche LLP following the ratification vote.